Learn More About Solid Biosciences’ Gene Therapy Trial for CPVT скачать в хорошем качестве

Learn More About Solid Biosciences’ Gene Therapy Trial for CPVT

Solid Biosciences’ Gene Therapy Trial for CPVT Part of the Living with SADS Webinar Series 🔑 Key Takeaways: How Gene ARTEMIS Therapy Works – The treatment uses an adeno-associated virus (AAV) to deliver a healthy copy of the calsequestrin gene (CASQ2), aiming to address the root cause of CPVT rather than just symptoms. Difference from Traditional Therapies – Unlike daily medications that manage arrhythmia risk, gene therapy is designed as a one-time treatment with potentially long-lasting or permanent effects. Clinical Trial Participation – The Artemis trial is currently enrolling patients, with eligibility and participation details shared during the session, emphasizing the importance of patient partnership in advancing research. Featured Speakers: Gabriel Brooks, MD – Chief Medical Officer, Solid Biosciences. Dr. Brooks leads the clinical strategy for neuromuscular and cardiac gene therapy programs. Annie Ganot – Senior Vice President & Head of Patient Advocacy, Solid Biosciences. Annie is a co-founder of Solid and a leader in building patient partnerships.